Polymorphisms associated with everolimus pharmacokinetics, toxicity and survival in metastatic breast cancer

PURPOSE: Metastatic breast cancer (MBC) progressing after endocrine therapy frequently activates PI3K/AKT/mTOR pathway. The BOLERO-2 trial showed that everolimus-exemestane achieves increased progression free survival (PFS) compared with exemestane. However, there is great inter-patient variability...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:PLoS One
Main Authors: Pascual, Tomas, Apellániz-Ruiz, María, Pernaut, Cristina, Cueto-Felgueroso, Cecilia, Villalba, Pablo, Álvarez, Carlos, Manso, Luis, Inglada-Pérez, Lucia, Robledo, Mercedes, Rodríguez-Antona, Cristina, Ciruelos, Eva
Format: Artigo
Sprog:Inglês
Udgivet: Public Library of Science 2017
Fag:
Research Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5519037/
https://ncbi.nlm.nih.gov/pubmed/28727815
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0180192
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker